Novel Protein May Help Detect Lou Gehrig’s Disease and Dementia, Mayo Clinic Finds

“This new finding sheds light on how the mutation causes these disorders, and it provides us with a marker that helps us track disease progression in patients with this disorder and potentially combat the disease,” says senior author Leonard Petrucelli, Ph.D., a molecular neuroscientist and director of the Department of Neuroscience at Mayo Clinic in Florida.

ALS TDI Enters Collaboration with to-BBB to Investigate Potential Treatments for ALS

CAMBRIDGE, Massachusetts, January 10, 2013 — The ALS Therapy Development Institute (ALS TDI) has entered into a new collaboration with to-BBB, a clinical stage biotechnology company focusing on enhanced drug delivery across the blood-brain barrier, to investigate potential treatments for ALS (aka Motor Neuron or Lou Gehrig’s disease).
“This partnership brings a new potential tool to [...]